Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 17, 2017

Primary Completion Date

September 19, 2018

Study Completion Date

September 19, 2018

Conditions
Developmental and/or Epileptic Encephalopathies
Interventions
DRUG

TAK-935

TAK-935 tablets.

DRUG

Placebo

TAK-935 placebo-matching tablets.

Trial Locations (11)

19107

Thomas Jefferson University, Philadelphia

20817

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

22903

University of Virginia Health Sciences Center, Charlottesville

29425

Medical University of South Carolina, Charleston

30318

Center for Integrative Rare Disease Research, Atlanta

33606

University of South Florida, Tampa

33952

Medsol Clinical Research Center, Port Charlotte

40504

Bluegrass Epilepsy Research, Lexington

63131

The Comprehensive Epilepsy Care Center for Children and Adults, St Louis

85004

Xenoscience, Phoenix

07601

Northeast Regional Epilepsy Group, Hackensack

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Healx AI

INDUSTRY

lead

Takeda

INDUSTRY